Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PLIANT THERAPEUTICS, INC. (PLRX)

Pliant Therapeutics Q2 net loss narrows to $22.4 million from $43.3 million

Positive Impact 3 of 5 earnings Written later

Pliant Therapeutics reported a second quarter 2026 net loss of $22.4 million, down from $43.3 million a year earlier, as operating expenses fell after the 2025 end of bexotegrast development in IPF and lower headcount. The company ended the quarter with $159.6 million in cash, cash equivalents and short-term investments and said that amount should fund operations into the second half of 2028. The filing did not include revenue or guidance figures.

Key points

  • Net loss was $22.4 million, or $0.36 per share, versus $43.3 million, or $0.71 per share, in the second quarter of 2025.
  • Research and development expenses were $16.7 million, down from $32.2 million; general and administrative expenses were $7.1 million, down from $13.4 million.
  • Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026, which the company expects to fund operations into the second half of 2028.
  • Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. were appointed to the board; interim data from the FORTIFY trial is expected in 2027.

The filing

CompanyPLIANT THERAPEUTICS, INC. (PLRX)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:10 PM ET
Accession number0001746473-26-000115

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.